APPROACHES TO WEST SYNDROME TREATMENT: WHICH AEDs HELP BETTER?
DOI:
https://doi.org/10.32461/2226-3209.1.2018.178360Abstract
Abstract. The study analyzes the effectiveness of short-term and long-term treatment of West syndrome with the help of different antiepileptic drugs (AEDs) (combined therapy with the inclusion of Tetracosactide in comparison with nonhormonal antiepileptic drugs). The RR risk ratio was calculated using Review Manager 5.2 (http://community.cochrane.org). A complete absence of seizures was considered as a favorable outcome. 150 children with confirmed West syndrome who received treatment at A.Yu.Ratner Pediatic Clinical Hospital №8 (Kazan, Russian Federation) were included into a retrospective observational study. 90 children treated with Tetracosactide in combination with AEDs were included into Group I. Group II consisted of 60 children who received any AEDs except Tetracosactide. The results showed that the effectiveness of Tetracosactide with complete absence of seizures as favorable outcome with short-term observation (at least 6 months) is higher than after treatment with other antiepileptic drugs in the absence of difference in safety. Long-term results of treatment (complete clinical remission during three
years or more) did not have a significant difference.
Keywords: West syndrome, Tetracosactide, antiepileptic drugs, epilepsy, effectiveness of treatment.
References
Wilmshurst J.M., Gaillard W.D., Vinayan K.P. et al. Summary of recommendations for the management of infantile
seizures: Task Force Report for the ILAE Commission of Pediatrics, Epilepsia, vol. 56, issue 8, e1185-97, 2015.
Hancock E.C., Osborne J.P., Edwards S.W. Treatment of infantile spasms, Cochrane Database of Systematic
Reviews, vol. 5, issue 6, CD001770, 2013.
Sorel L., Dusaucy-Bayloye H. A propos de 21 cas d‘hypsarythmie de Gibbs. Son Traitement spectaculaire par
l’ACTH, Acta Neurol Psychiatr Belg, vol. 58, issue 2, pp. 130-141, 1958.
Cilio M.R., Kartashov A.I., Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy,
Epilepsy Res, vol. 47, pp. 1–7, 2001.
Lawlor K.M., Devlin A.M. Levetiracetam in the treatment of infantile spasms, Eur J Paediatr Neurol., vol. 9: e19–
e22, 2005.
Mikati M.A., Fayad M., Koleilat M. et al. Efficacy, tolerability, and kinetics of lamotrigine in infants, J Pediatr, vol.
, pp. 31–35, 2002.
Peltzer B., Alonso W.D., Porter B.E. Topiramate and adrenocorticotropic hormone (ACTH) as initial treatment for
infantile spasms, J Child Neurol, vol, 24, issue 4, pp. 400-405, 2009.
Weber A., Cole J.W., Mytinger J.R. Infantile spasms respond poorly to Topiramate, Pediatr Neurol, vol. 53, issue 2,
pp. 130-134.
Askalan R., Mackay M., Brian J. Prospective preliminary analysis of the development of autism and epilepsy in
children with infantile spasms, J Child Neurol, vol. 18, issue 3, pp. 165-170, 2003.
Wild J.M., Chiron C., Ahn H. et al. Visual field loss in patients with refractory partial epilepsy treated with
vigabatrin: final results from an open-label, observational, multicentre study, CNS Drugs, vol. 23, issue 11, pp. 965-
, 2009.
Pellock J.M., Hrachovy R., Shinnar S. Infantile spasms: a U.S. consensus report. Epilepsia, vol. 51, issue 10, pp.
-2189, 2010.
Wheless J.W., Gibson P.A., Rosbeck K.L. Infantile spasms (West syndrome): update and resources for pediatricians
and providers to share with parents. BMC Pediatr. vol. 12, p. 108, 2012.
Hrachovy R.A., Frost J.D. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West
syndrome), J Clin Neurophysiol, vol. 20, issue 6, pp. 408-425, 2003.
Mackay M.T., Weiss S.K., Adams-Webber T. et al. Practice parameter: medical treatment of infantile spasms:
report of the Аmerican Academy of Neurology and the Child Neurology Society, Neurology, vol. 62, issue 10, pp.
–1681, 2004.
Rajaraman R.R., Lay J., Alayari A. et al. Prevention of infantile spasms relapse: Zonisamide and topiramate provide
no benefit, Epilepsia, vol. 57, issue 8, pp. 1280-1287.
O'Callaghan F.J., Edwards S.W., Alber F.D. et al. Safety and effectiveness of hormonal treatment versus hormonal
treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial, Lancet Neurol,
vol. 16, pp. 33-42, 2017.
Ziganshina L.E., Gamirova R.G, Abakumova T.R. Gabapentin monotherapy for epilepsy, Cochrane Database of
Systematic Reviews, vol. 6: CD012710, 2017.
Gamirova R., Akhutina T., Gorobets E., Shaykhutdinova R. The effect of antiepileptic therapy on the development
of cognitive functions in children with epilepsy: introduction to the problem, Helix, vol. 8, issue 1, pp. 2941-2944,
Esin R.G., Gorobets E.A., Esin O.R. Speech disorders in patients with vascular encephalopathy, European Journal
of Clinical Investigation, t. 47, pp. 56-57, 2017.
Gorobets, E.A., Kulsharipova, R.E., Lotfullina, N.Z. Semantico-phonological disorders in patients with Wernicke's
aphasia, Social Sciences (Pakistan), vol. 10, issue 5, pp. 566-570, 2015.
Riikonen R. Recent Advances in the Pharmacotherapy of Infantile Spasms, CNS Drugs, vol. 28, pp. 279–290,
Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
